Taiwan Liposome Company Signs EU and US Collaboration Agreement for Antifungal Liposomal Amphotericin B Drug

TAIPEI, Taiwan, Dec. 18, 2013 (GLOBE NEWSWIRE) -- Taiwan Liposome Company Limited (TLC) (4152.TWO) announced today the signature of their collaboration agreement with Sandoz AG, an affiliate within the generics division of Novartis NVS. Sandoz will be responsible for the commercialization of TLC's Liposomal Amphotericin B product in EU and US territories.

"We are very pleased to have an extremely strong player in the generic market such as Sandoz to distribute our Liposomal Amphotericin B product in EU and US," said Dr. Keelung Hong, Chairman and CEO of TLC. "We also anticipate this deal to be a collaborative relationship between TLC and Sandoz, which I'm sure both parties would benefit tremendously from."

Prior to the Sandoz deal, TLC has licensed out the distribution rights for its Liposomal Amphotericin B product in Taiwan and South Korea markets to YSP (3705.TW) and SCD (Ticker Number: 000250:KS) respectively, both are amongst the top local players in their territories. 

About TLC

Incorporated in 1997, Taiwan Liposome Company is a biopharmaceutical company engaging in research, development and commercialization of proprietary drug delivery system for improving the treatment of cancer, ophthalmic conditions, and infectious diseases. TLC founded and led by renowned scientist, Dr. Keelung Hong, who has over 30 years of research and development experience in liposomes with over 100 publications. TLC also has a team of researchers, management, production experts, and advisors who are building the company into an organization recognized for its excellence in targeted delivery and rapid advancement of products. TLC currently operates from Headquarter in Taipei (Taiwan), and subsidiary offices in South San Francisco (US) and Leiden (The Netherlands).

For more information, please visit www.tlcbio.com